TPM203 / Topas Therap - LARVOL DELTA

Immunoregulatory effects of TPM203 peptide-nanoparticle therapy in pemphigus vulgaris. (PubMed, Br J Dermatol) - No abstract available

Journal • Dermatology • Immunology • Pemphigus Vulgaris

Safety, tolerability, pharmacokinetics, and pharmacodynamic effects of desmoglein 3-peptide-coupled tolerizing nanoparticles in pemphigus. (PubMed, Br J Dermatol) - P1 | "Administered for the first time in humans, TPM203 was shown as a safe and well-tolerated nanoparticle-based therapeutic approach with the potential to promote tolerance induction in PV, justifying further clinical development in PV and other autoimmune diseases (EudraCT:2019-001727-12)."

Journal • PK/PD data • Dermatology • Immunology • Pemphigus Vulgaris • CD27 • CD4 • HLA-DRB1

Safety, tolerability, and pharmacokinetics of TPM203, a tolerizing Topas particle mixture in pemphigus vulgaris: preliminary results from a phase 1, first in man study (EudraCT Number: 2019-001727-12) (EADV 2023) - "No immunosuppressive/immunomodulatory treatment was allowed, other than ≤10 mg/d of prednisone equivalent. In conclusion, escalating single doses of TPM203 were safe and well tolerated in PV patients with no or low/moderate disease activity. Despite the limitations of the study (small patient number, single TPM203 administration, and short observation period), these preliminary data could indicate that this T cell-targeted approach might modulate the immune response in PV patients by increasing Treg cells and decreasing Th17 and memory B cells."

Clinical • IO biomarker • P1 data • PK/PD data • Dermatology • Immunology • Novel Coronavirus Disease • Pemphigus Vulgaris • CD27 • CD4 • HLA-DRB1

Safety, tolerability and pharmacokinetics of TPM203, a first-in-man T cell-tolerizing Topas particle mixture in pemphigus vulgaris (PV): preliminary results from a phase 1 study (TPV11) (WCD 2023) - "In conclusion, escalating single doses of TPM203 were safe and well tolerated in the studied PV patients. The preliminary data suggest that this T cell-targeted approach modulates the pathology of PV by increasing Treg and decreasing Th17 and memory B cells"

Clinical • Late-breaking abstract • P1 data • PK/PD data • Dermatology • Immunology • Novel Coronavirus Disease • Pemphigus Vulgaris • CD27 • HLA-DRB1